On the stock market since 1980, it operates in the world of health and science. It has 4 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $123.1M a year. A small number, but proof the product has real buyers.
There is $80.5M in the vault; even if every debt were paid off, $80.5M would remain.
Over the last 12 months, company executives reported 50 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $22.4M against $123.1M in annual sales.
On our five-subject report card, AIKI sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AIKI is a high-risk stock — not yet profitable, and its future rides on its product catching on.